* Linagliptin (Tradjenta) is the newest drug approved for type 2 diabetes.
* Linagliptin promotes the function of endogenous incretins, hormones that work to lower elevated blood glucose levels.
* The drug doesn't usually cause hypoglycemia and is generally well tolerated.
Diane S. Aschenbrenner is the course coordinator for undergraduate pharmacology at Johns Hopkins University School of Nursing in Baltimore, MD. She also coordinates Drug Watch: firstname.lastname@example.org.